Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYCAMORE trial of adalimumab plus methotrexate for juvenile idiopathic arthritis-associated uveitis
ISRCTN10065623Phase 3Completed
- Sponsor
- University Hospitals Bristol and Weston NHS Foundation Trust
- Start
- Oct 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in uveitis and juvenile idiopathic arthritis (JIA) comparing Adalimumab + methotrexate with Placebo + methotrexate (2 arms). Primary endpoint: Time to treatment failure. Started Oct 2011; status: completed.
02
Drugs
adalimumabmethotrexate
03
Conditions
uveitisjuvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on ISRCTN10065623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10065623.